Compare Adaptive Biotechnologies Corp (ADPT) vs Duke Energy Corp (DUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Duke Energy Corp — how do they compare? Adaptive Biotechnologies Corp trades at $24.93 (market cap $4.04B), while Duke Energy Corp trades at $123.32 (market cap $96.05B). The key difference: Duke Energy Corp is far larger — about 23.8× Adaptive Biotechnologies Corp's market cap, and Duke Energy Corp pays a 3.52% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DUK | |
|---|---|---|
Market Cap | $4.04B | $96.05B |
Sector | Health | Utilities |
52-Week High | $25.45 | $133.46 |
52-Week Low | $12.30 | $113.99 |
Enterprise Value | $4.10B | $188.56B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Duke Energy (DUK) trades at $121.19, down 2.93% on the day, with a bearish technical signal. The company reported strong Q2 2026 earnings of $1.43 per share, beating estimates, and maintains solid fundamentals with a 15.78% net income margin. Recent news highlights operational challenges from storms affecting customers but also strategic initiatives like a $35 million equity units offering and data center growth opportunities.
The outlook is mixed; fundamentals are robust with consistent earnings beats and a healthy dividend, but technical weakness and high debt levels pose risks. Analyst consensus is a 'Hold' with a $136.17 price target, suggesting cautious optimism for long-term investors amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
